Items without sitelinks
From determinar.ia.br - Determine suas informações
Showing below up to 50 results in range #9,601 to #9,650.
- Intentional self-harm by exposure to or harmful effects of chloramphenicol group (Q103209)
- Intentional self-harm by exposure to or harmful effects of centrally-acting or adrenergic-neuron-blocking agents (Q103208)
- Intentional self-harm by exposure to or harmful effects of aminophylline, theophylline (Q103207)
- Intentional self-harm by exposure to or harmful effects of terbutaline (Q103206)
- Intentional self-harm by exposure to or harmful effects of tetracyclines (Q103205)
- Intentional self-harm by exposure to or harmful effects of ganglionic blocking drugs (Q103204)
- Intentional self-harm by exposure to or harmful effects of predominantly alpha-adrenoreceptor agonists (Q103203)
- Intentional self-harm by exposure to or harmful effects of cephalosporins or other beta-lactam antibiotics (Q103202)
- Intentional self-harm by exposure to or harmful effects of other parasympathomimetics (Q103201)
- Intentional self-harm by exposure to or harmful effects of anticholinesterase agents (Q103200)
- Intentional self-harm by exposure to or harmful effects of other anti-common-cold drugs (Q103199)
- Intentional self-harm by exposure to or harmful effects of antitussives (Q103198)
- Intentional self-harm by exposure to or harmful effects of natural blood or blood products (Q103197)
- Intentional self-harm by exposure to or harmful effects of thrombolytic drug (Q103196)
- Intentional self-harm by exposure to or harmful effects of other drugs acting on muscles (Q103195)
- Intentional self-harm by exposure to or harmful effects of unspecified drugs acting on muscles (Q103194)
- Intentional self-harm by exposure to or harmful effects of anticoagulant antagonists, vitamin K or other coagulants (Q103193)
- Intentional self-harm by exposure to or harmful effects of skeletal muscle relaxants (Q103192)
- Intentional self-harm by exposure to or harmful effects of enzymes (Q103191)
- Intentional self-harm by exposure to or harmful effects of antithrombotic drugs (Q103190)
- Intentional self-harm by exposure to or harmful effects of acidifying or alkalising agents (Q103189)
- Intentional self-harm by exposure to or harmful effects of other fibrinolysis-affecting drugs (Q103188)
- Intentional self-harm by exposure to or harmful effects of other primarily systemic agents, not elsewhere classified (Q103187)
- Intentional self-harm by exposure to or harmful effects of plasma substitutes (Q103186)
- Intentional self-harm by exposure to or harmful effects of oxytocic drugs (Q103185)
- Intentional self-harm by exposure to or harmful effects of iron or its compounds (Q103184)
- Intentional self-harm by exposure to or harmful effects of anticoagulants (Q103183)
- Intentional self-harm by exposure to or harmful effects of immunosuppressive agents (Q103182)
- Intentional self-harm by exposure to or harmful effects of vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations (Q103181)
- Intentional self-harm by exposure to or harmful effects of other hormones or synthetic substitutes (Q103180)
- Intentional self-harm by exposure to or harmful effects of other antineoplastic drugs (Q103179)
- Intentional self-harm by exposure to or harmful effects of antineoplastic natural products (Q103178)
- Intentional self-harm by exposure to or harmful effects of androgens or anabolic congeners (Q103177)
- Intentional self-harm by exposure to or harmful effects of camphor (Q103176)
- Intentional self-harm by exposure to or harmful effects of antithyroid drugs (Q103175)
- Intentional self-harm by exposure to or harmful effects of other H1-receptor antagonists (Q103174)
- Intentional self-harm by exposure to or harmful effects of other hormone antagonists (Q103173)
- Intentional self-harm by exposure to or harmful effects of diphenhydramine (Q103172)
- Intentional self-harm by exposure to or harmful effects of otorhinolaryngological drugs or preparations (Q103171)
- Intentional self-harm by exposure to or harmful effects of glucocorticoids or synthetic analogues (Q103170)
- Intentional self-harm by exposure to or harmful effects of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified (Q103169)
- Intentional self-harm by exposure to or harmful effects of antiallergic or antiemetic drugs (Q103168)
- Intentional self-harm by exposure to or harmful effects of thyroid hormones or substitutes (Q103167)
- Intentional self-harm by exposure to or harmful effects of unspecified hormones or synthetic substitutes (Q103166)
- Intentional self-harm by exposure to or harmful effects of insulin or oral hypoglycaemic drugs (Q103165)
- Intentional self-harm by exposure to or harmful effects of oral contraceptives (Q103164)
- Intentional self-harm by exposure to or harmful effects of unspecified hormone antagonists (Q103163)
- Intentional self-harm by exposure to or harmful effects of other estrogens or progestogens (Q103162)
- Intentional self-harm by exposure to or harmful effects of anterior pituitary hormones (Q103161)
- Intentional self-harm by exposure to or harmful effects of antineoplastic antimetabolites (Q103160)
